Current and future biomarkers for pancreatic adenocarcinoma (Q38670577)

5 September 2017

1 reference

title

Current and future biomarkers for pancreatic adenocarcinoma (English)

1 reference

5 September 2017

0 references

Sven H Loosen

1

1 reference

5 September 2017

Ulf P Neumann

2

1 reference

5 September 2017

Christian Trautwein

3

1 reference

5 September 2017

Christoph Roderburg

4

1 reference

5 September 2017

Tom Luedde

5

1 reference

5 September 2017

publication date

1 June 2017

1 reference

5 September 2017

1 reference

5 September 2017

volume

39

1 reference

5 September 2017

issue

6

1 reference

5 September 2017

page(s)

1010428317692231

1 reference

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Diagnostic performance of serum macrophage inhibitory cytokine-1 in pancreatic cancer: a meta-analysis and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Serum biomarker panels for the detection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Identification of novel genes coding for small expressed RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNAs: target recognition and regulatory functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA expression profiles classify human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNAs accurately identify cancer tissue origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Expression profiling identifies microRNA signature in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA miR-155 is a biomarker of early pancreatic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Long noncoding RNAs: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Circulating RNAs as new biomarkers for detecting pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Alternative processing of the U2 small nuclear RNA produces a 19-22nt fragment with relevance for the detection of non-small cell lung cancer in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Pathology and molecular genetics of pancreatic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Whole genomes redefine the mutational landscape of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

EMT and dissemination precede pancreatic tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoi

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Performance status assessment in cancer patients. An inter-observer variability study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Prognostic and predictive markers in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Survival and prognostic factors of unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Modelling prognostic factors in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1010428317692231

21 January 2018

Identifiers

DOI

10.1177/1010428317692231

1 reference

5 September 2017

1 reference